Autolus Therapeutics plc Earnings Per Share Disclosure
| Year Ended December 31, | |||||||||||||||||
| 2025 | 2024 | ||||||||||||||||
| Numerator | |||||||||||||||||
| Net loss | $ | (287,528) | $ | (220,662) | |||||||||||||
| Net Loss Attributable to Ordinary Shareholders - Basic and Diluted | $ | (287,528) | $ | (220,662) | |||||||||||||
| Denominator | |||||||||||||||||
| Weighted-average number of ordinary shares used in net loss per share - basic and diluted | 266,138,224 | 255,161,038 | |||||||||||||||
| Net Loss Per Share - Basic and Diluted | $ | (1.08) | $ | (0.86) | |||||||||||||
| December 31, | ||||||||||||||
| 2025 | 2024 | |||||||||||||
Unvested restricted stock units | 92,500 | 32,412 | ||||||||||||
Outstanding share options | 31,130,935 | 20,754,316 | ||||||||||||
| Warrants | 3,265,306 | 3,265,306 | ||||||||||||
| Total | 34,488,741 | 24,052,034 | ||||||||||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 27, 2026 | Showing above |
| 2024 | Mar 20, 2025 | |
| 2023 | Mar 21, 2024 | |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.